Gral Medical S.R.L. — Clinical Trial Site

17 Registered trials

9 Currently recruiting

Organisation

Gral Medical S.R.L.

Location

Bucharest, Romania

Identifier

ORG-100040333

Address

Strada Popovici Traian 79-91, 031422, Romania

Departments

6111:Oncology
Departament Clinic Oncologie Medicala
Medical Oncology
Oncologie Medicala
Oncology
Sectia Oncologie Medicala

Clinical trials at this site (17)

Search interface

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis. Pending

2024-519298-21-00 Cancer-Associated Thrombosis (CAT). 5
A phase 2 placebo-controlled trial to investigate visugromab in combination with immunochemotherapy (ICT) in first-line treatment of partici… Recruiting

2024-516792-32-01 Metastatic non-squamous non-small cell lung cancer 4 2025-07-18
Visugromab in Cachexia International Trial Recruiting

2025-523533-25-00 Cancer-associated Cachexia 10 2026-03-26
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung… Recruiting

2024-517780-24-00 Lung Cancer 5 2025-09-18
Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer… Recruiting

2024-516982-35-00 Ovarian Cancer 5 2025-09-11
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un… Recruiting

2023-508613-17-00 Neoplasms, Head and Neck 5 2024-05-29
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib… Recruiting

2023-503708-10-00 Locally advanced or metastatic breast cancer 5 2024-02-20
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended

2023-503428-24-00 Neoplasms, Head and Neck 4 2024-01-19
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended

2023-503501-11-00 Metastatic Non-small Cell Lung Cancer 5 2023-02-09
Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended

2023-509429-37-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5 2022-10-03
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo®… Ended

2023-507865-24-00 Advanced (unresectable/metastatic) melanoma 5 2025-03-28
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended

2022-502196-31-00 Advanced or Recurrent Endometrial Cancer 10 2023-08-21
A trial to show the similarity in effects, safety and immune response of FYB206 compared to Keytruda in people with metastatic non-squamous … Ended

2023-509766-37-00 NSCLC 5